



WELL HEALTH TECHNOLOGIES CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025

Expressed in thousands of Canadian dollars

(Unaudited)

WELL HEALTH TECHNOLOGIES CORP.

Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

	Three months ended September 30, 2025		September 30, 2024 Restated (Note 2(c))		Nine months ended September 30, 2025		September 30, 2024 Restated (Note 2(c))	
Revenue (Note 5)	364,599		234,135		1,015,409		684,930	
Expenses								
Cost of sales (excluding depreciation and amortization)	(198,828)		(139,487)		(573,427)		(404,595)	
General and administrative (Note 6)	(103,962)		(76,775)		(293,119)		(221,740)	
Depreciation and amortization	(26,520)		(17,476)		(71,461)		(51,343)	
Share-based payments (Note 16)	(5,949)		(2,141)		(14,229)		(12,383)	
Impairment charge (Note 12)	(10,506)		-		(10,506)		-	
Foreign exchange (loss) gain	(1,734)		(62)		(786)		42	
Operating income (loss)	17,100		(1,806)		51,881		(5,089)	
Interest income (Note 7)	342		255		1,324		772	
Interest expense (Note 7)	(16,228)		(9,103)		(40,543)		(28,333)	
Time-based earnout expense (Note 8)	(1,583)		(1,829)		(6,935)		(3,956)	
Change in fair value of investments (Note 10)	(311)		(77,092)		(22,795)		53,192	
Change in fair value of derivative liability (Note 15(b))	(488)		-		1,642		-	
Gain on disposal of assets and investments (Note 19)	10,950		33		10,974		11,317	
Share of net loss of associates	(146)		(1,832)		(2,643)		(2,719)	
Other expenses	(2,727)		(895)		(6,190)		(6,928)	
Income (loss) before income tax	6,909		(92,269)		(13,285)		18,256	
Income tax (expense) recovery	(9,562)		3,843		(14,256)		12,675	
Net (loss) income	(2,653)		(88,426)		(27,541)		30,931	
Net income (loss) attributable to:								
Owners of WELL Health Technologies Corp.	4,172		(90,114)		(30,251)		24,567	
Non-controlling interests	(6,825)		1,688		2,710		6,364	
	(2,653)		(88,426)		(27,541)		30,931	
Other comprehensive income (loss):								
<i>Items that may be subsequently reclassified to profit or loss:</i>								
Exchange difference on translation of foreign operations	8,712		(7,030)		(15,571)		10,813	
Fair value (loss) gain on derivative instruments designated in cash flow hedges	-		(862)		-		315	
Reclassification of fair value gain (loss) on derivative instruments to net income	107		(130)		329		(389)	
Total comprehensive income (loss)	6,166		(96,448)		(42,783)		41,670	
Total comprehensive income (loss) attributable to:								
Owners of WELL Health Technologies Corp.	13,010		(98,033)		(45,958)		35,192	
Non-controlling interests	(6,844)		1,585		3,175		6,478	
	6,166		(96,448)		(42,783)		41,670	
Earnings (loss) per share attributable to WELL Health Technologies Corp.								
Basic	0.02		(0.36)		(0.12)		0.10	
Diluted	0.02		(0.36)		(0.12)		0.10	
Weighted average number of common shares outstanding								
Basic	253,663,389		248,803,453		251,796,729		246,006,544	
Diluted	257,218,385		248,803,453		251,796,729		254,575,261	

The accompanying notes are an integral part of these condensed interim consolidated financial statements

WELL HEALTH TECHNOLOGIES CORP.

Consolidated Statements of Financial Position

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated)

As at	September 30, 2025	December 31, 2024
Assets		
Current		
Cash and cash equivalents	82,546	131,669
Accounts and other receivables (Note 9(a))	198,509	184,505
Contract assets (Note 9(b))	20,436	-
Inventory	2,238	2,691
Prepayments and other assets	40,940	27,248
Total current assets	344,669	346,113
Financial assets at fair value through profit and loss (Note 10)	14,717	158,476
Investments accounted for using the equity method (Note 11)	3,105	15,310
Prepayments and other assets – non-current	7,174	4,945
Property and equipment	116,968	101,762
Intangible assets (Note 12)	760,510	573,962
Goodwill (Note 12)	733,960	565,117
Deferred tax assets	37,972	41,588
Total assets	2,019,075	1,807,273
Liabilities and equity		
Current		
Accounts payable and accrued liabilities	107,270	86,583
Deferred revenue (Note 13)	44,169	59,450
Contract liabilities (Note 9(b))	21,783	-
Deferred acquisition costs (Note 14(a))	25,587	14,585
Other liabilities (Note 14(b))	42,737	27,982
Advances payable (Note 14(c))	69,527	165,441
Loans and borrowings (Note 15(a))	6,449	5,534
Convertible debentures and derivative liability (Note 15(b))	28,713	3,850
Lease liability	26,398	18,651
Total current liabilities	372,633	382,076
Deferred acquisition costs – non-current (Note 14(a))	35,124	16,354
Other liabilities – non-current (Note 14(b))	2,237	2,292
Loans and borrowings – non-current (Note 15(a))	389,161	284,731
Convertible debentures and derivative liability – non-current (Note 15(b))	60,604	51,244
Redeemable preferred shares (Note 15(c))	53,744	48,054
Lease liability – non-current	64,470	61,079
Deferred tax liabilities	47,642	31,722
Total liabilities	1,025,615	877,552
Equity		
Share capital (Note 16)	807,683	784,873
Share-based payments reserve (Note 16)	21,509	21,578
Convertible debenture options reserve	25,043	25,043
Accumulated other comprehensive income	51,381	67,088
Accumulated deficit	(61,226)	(30,975)
Equity attributable to owners of WELL Health Technologies Corp.	844,390	867,607
Non-controlling interests	149,070	62,114
Total equity	993,460	929,721
Total equity and liabilities	2,019,075	1,807,273
<i>Commitments and contingencies (Notes 20 and 21(c))</i>		
<i>Events after the reporting period (Notes 23)</i>		

Approved by the Directors:

"Hamed Shahbazi"

"Thomas Liston"

WELL HEALTH TECHNOLOGIES CORP.

Consolidated Statements of Changes in Equity

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share amounts)

	Attributable to owners of WELL Health Technologies Corp.								Total Equity
	Number of Shares	Share Capital	Share-based payments reserve	Convertible debenture options reserve	Accumulated Other Comprehensive Income	Accumulated Deficit	Total	Non-controlling Interests	
Balance at December 31, 2024	249,091,940	784,873	21,578	25,043	67,088	(30,975)	867,607	62,114	929,721
Stock options exercised (Note 16)	140,500	595	(149)	-	-	-	446	-	446
Shares issued for RSUs/PSUs (Note 16)	2,723,630	12,053	(12,053)	-	-	-	-	-	-
Shares issued for settlement of deferred acquisition costs (Note 14(a))	2,170,275	11,285	-	-	-	-	11,285	-	11,285
Share-based payments (Note 16)	-	-	14,229	-	-	-	14,229	-	14,229
Normal course issuer bid (Note 16)	(232,300)	(1,123)	-	-	-	-	(1,123)	-	(1,123)
Non-controlling interests via business combination (Note 19(a))	-	-	-	-	-	-	-	98,114	98,114
Distributions paid to non-controlling interests	-	-	-	-	-	-	-	(17,811)	(17,811)
Changes in non-controlling interests	-	-	(2,096)	-	-	-	(2,096)	3,478	1,382
Foreign currency translation of foreign subsidiaries	-	-	-	-	(16,036)	-	(16,036)	465	(15,571)
Derivative instruments designated in cash flow hedges	-	-	-	-	329	-	329	-	329
Net (loss) income for the period	-	-	-	-	-	(30,251)	(30,251)	2,710	(27,541)
Balance at September 30, 2025	253,894,045	807,683	21,509	25,043	51,381	(61,226)	844,390	149,070	993,460
Balance at December 31, 2023	241,427,825	751,550	29,005	25,043	25,652	(63,584)	767,666	78,480	846,146
Stock options exercised	1,583,907	4,958	(1,843)	-	-	-	3,115	-	3,115
Shares issued for RSUs/PSUs	3,869,634	19,619	(19,619)	-	-	-	-	-	-
Shares issued for settlement of deferred acquisition costs	1,767,874	6,899	-	-	-	-	6,899	-	6,899
Shares issued for time-based earnout payments	537,563	2,144	-	-	-	-	2,144	-	2,144
Share-based payments (Note 16)	-	-	12,383	-	-	-	12,383	-	12,383
Normal course issuer bid (Note 16)	(252,800)	(1,052)	-	-	-	-	(1,052)	-	(1,052)
Distributions paid to non-controlling interests	-	-	-	-	-	-	-	(22,516)	(22,516)
Other transactions with non-controlling interest	-	-	22	-	-	-	22	(382)	(360)
Foreign currency translation of foreign subsidiaries (restated)	-	-	-	-	10,699	-	10,699	114	10,813
Derivative instruments designated in cash flow hedges	-	-	-	-	(74)	-	(74)	-	(74)
Net income for the period (restated)	-	-	-	-	-	24,567	24,567	6,364	30,931
Balance at September 30, 2024	248,934,003	784,118	19,948	25,043	36,277	(39,017)	826,369	62,060	888,429

The accompanying notes are an integral part of these condensed interim consolidated financial statements

WELL HEALTH TECHNOLOGIES CORP.

Consolidated Statements of Cash Flows

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated)

	Nine months ended	
	September 30, 2025	September 30, 2024 Restated (Note 2(c))
Cash flows provided by (used in)		
Operating activities		
Net (loss) income for the period	(27,541)	30,931
<i>Adjustments to net (loss) income for non-cash items:</i>		
Interest income accretion	(495)	(469)
Interest expense accretion	22,066	11,269
Impairment charge (Note 12)	10,506	-
Time-based earnout payments settled via shares	-	2,144
Unrealized foreign exchange and others	144	2,828
Loss (gain) on revaluation of deferred acquisition cost liability	7,074	(1,237)
Change in fair value of investments	22,795	(53,192)
Change in fair value of derivative liability	(1,642)	-
Depreciation and amortization	71,461	51,343
Gain on disposal of investments	(10,960)	(11,317)
Share of net loss of associates	2,643	2,719
Share-based payments (Note 16)	14,229	12,383
(Gain) loss on deferred acquisition cost settled in shares	(1,931)	175
Non-cash loss included in other expenses	753	752
Deferred income taxes	480	(20,174)
Change in non-cash operating items (Note 22)	(33,739)	(59,794)
Net cash provided by (used in) operating activities	75,843	(31,639)
Investing activities		
Business acquisitions, net of cash acquired (Notes 19 and 22)	(31,719)	(1,147)
Asset acquisitions (Notes 19 and 22)	(11,781)	-
Net proceeds from disposal of investments	15,103	2,390
Equity and debt investments in associates and others (Note 22)	(6,807)	(73)
Acquisition of property and equipment and internally generated intangible assets	(19,390)	(10,265)
Working capital/Indemnity holdbacks	(2,234)	(1,252)
Settlement of deferred acquisition costs (Note 14(a))	(2,717)	(6,742)
Net cash used in investing activities	(59,545)	(17,089)
Financing activities		
Shares repurchased under NCIB (Note 16)	(1,123)	(1,052)
Payment of interest on convertible debentures (Note 15(b))	(2,675)	(1,925)
Advances received from billing service provider (Note 14(c))	-	143,751
Repayments of advances to billing service provider (Note 14(c))	(91,317)	-
Proceeds from loans and borrowings	111,134	32,724
Repayments of loans and borrowings	(44,647)	(69,414)
Proceeds from stock options exercised	446	3,115
Transactions with non-controlling interests	(15,992)	(22,816)
Lease payments	(19,713)	(14,633)
Lease payments received	943	746
Net cash (used in) provided by financing activities	(62,944)	70,496
Effects of foreign exchange difference on cash and cash equivalents	(2,477)	256
Cash reclassified from assets held for sale	-	703
Net change in cash	(49,123)	22,024
Cash and cash equivalents – beginning of period	131,669	43,423
Cash and cash equivalents – end of period	82,546	66,150
Cash paid for:		
Interest	(21,177)	(19,349)
Income tax	(10,837)	(3,957)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

1. Nature of Operations

WELL Health Technologies Corp. (the "Company" or "WELL") is a practitioner-focused digital healthcare company. WELL's overarching mission is to positively impact health outcomes by leveraging technology to empower healthcare practitioners and their patients globally. The Company was incorporated under the Business Corporations Act of British Columbia on November 23, 2010. The Company's common shares trade on the Toronto Stock Exchange (the "TSX") under the symbol WELL.

The Company's head office is located at Suite 550 - 375 Water Street, Vancouver, BC, V6B 5C6.

These condensed interim consolidated financial statements were approved by the Company's Board of Directors and authorized for issuance on November 5, 2025.

2. Basis of Presentation

(a) Statement of compliance

These condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with IFRS[®] Accounting Standards as issued by the International Accounting Standards Board ("IFRS Accounting Standards") applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. These condensed interim consolidated financial statements should be read in conjunction with the December 31, 2024 audited annual consolidated financial statements, which have been prepared in accordance with IFRS Accounting Standards.

These condensed interim consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. All financial information in these condensed interim consolidated financial statements, except share and per share amounts, is presented in thousands of Canadian dollars, which is the functional currency of the Company. All amounts are rounded to the nearest thousands of Canadian dollars.

(b) Foreign currency translation

The condensed interim consolidated financial statements are presented in Canadian dollars. Each subsidiary determines its functional currency based on the primary economic environment in which it operates.

Assets and liabilities of foreign subsidiaries with a different functional currency are translated into Canadian dollars using exchange rates in effect at the balance sheet date. Revenues and expenses are translated at average rates during the period. Translation reserve adjustments are recorded in translation reserve within equity and are reclassified to earnings upon disposal of the foreign operation. Foreign currency transactions are recorded at exchange rates in effect at the transaction date, with resulting gains or losses from remeasurement of monetary items recognized in earnings.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(c) Restatements of prior periods

During the year ended December 31, 2024, the Company's 70%-owned Delaware subsidiary, Circle Medical Technologies, Inc. ("Circle Medical"), performed certain patient services, collected cash from its customers and recognized revenue. While preparing its audited annual consolidated financial statements for the year ended December 31, 2024, the Company determined that it had not met revenue recognition criteria related to right to payment under IFRS 15, "Revenue from Contracts with Customers" in relation to these patient services. As a consequence, revenue had been overstated in the Company's condensed interim consolidated financial statements for each of the periods ended March 31, 2024, June 30, 2024 and September 30, 2024. The Company has retrospectively restated certain financial information reported in its condensed interim consolidated financial statements for these periods. In addition to the restatements relating to Circle Medical revenue, the Company has also retrospectively restated the classification of the advance payments received from Change Healthcare in the consolidated statements of cash flows in the Company's condensed consolidated interim financial statements for each of the periods ended March 31, 2024, June 30, 2024 and September 30, 2024. Such cash flows were previously reported as operating activities and have been restated as financing activities. The following table summarizes the impact of the restatement on the condensed interim consolidated statement of income for the three and nine months ended September 30, 2024:

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

	<u>Impact for three months ended</u> <u>September 30, 2024</u>			<u>Impact for nine months ended</u> <u>September 30, 2024</u>		
	As previously Reported	Adjustments	As restated	As previously Reported	Adjustments	As restated
<u>Consolidated Statement of Income</u>						
Revenue	251,739	(17,604)	234,135	726,448	(41,518)	684,930
Net (loss) income before income tax	(74,665)	(17,604)	(92,269)	59,774	(41,518)	18,256
Income tax expense (recovery)	1,087	(4,930)	(3,843)	(1,050)	(11,625)	(12,675)
Net (loss) income	(75,752)	(12,674)	(88,426)	60,824	(29,893)	30,931
Net (loss) income attributable to:						
Owners of Well Health Technologies Corp.	(81,192)	(8,922)	(90,114)	45,612	(21,045)	24,567
Non-controlling interests	5,440	(3,752)	1,688	15,212	(8,848)	6,364
	(75,752)	(12,674)	(88,426)	60,824	(29,893)	30,931
Other comprehensive (loss) income	(8,386)	364	(8,022)	10,447	292	10,739
Total comprehensive (loss) income	(84,138)	(12,310)	(96,448)	71,271	(29,601)	41,670
Total comprehensive (loss) income attributable to:						
Owners of Well Health Technologies Corp.	(89,475)	(8,558)	(98,033)	55,945	(20,753)	35,192
Non-controlling interests	5,337	(3,752)	1,585	15,326	(8,848)	6,478
	(84,138)	(12,310)	(96,448)	71,271	(29,601)	41,670
Earnings per share attributable to WELL Technologies Corp.						
Basic	(0.33)	(0.03)	(0.36)	0.19	(0.09)	0.10
Diluted	(0.33)	(0.03)	(0.36)	0.19	(0.09)	0.10
<u>Consolidated Statement of Changes in Equity</u>						
Foreign currency translation of foreign subsidiaries	(7,394)	364	(7,030)	10,521	292	10,813
Net (loss) income	(75,752)	(12,674)	(88,426)	60,824	(29,893)	30,931
Total equity as at September 30, 2024	918,030	(29,601)	888,429	918,030	(29,601)	888,429
<u>Consolidated Statement of Cashflows</u>						
Net cash provided by (used in) operating activities	57,884	(64,426)	(6,542)	112,112	(143,751)	(31,639)
Net cash (used in) provided by financing activities	(32,478)	64,426	31,948	(73,255)	143,751	70,496

3. Material Accounting Policy Information

- The preparation of these condensed interim consolidated financial statements is based on accounting principles and practices consistent with those used in the preparation of the Company's December 31, 2024 audited annual consolidated financial statements.
- The International Accounting Standards Board ("IASB") issued the following new accounting standards or amendments that will become effective on future dates.

IFRS 9 and IFRS 7 Amendments

On May 30, 2024, the IASB issued amendments to IFRS 9, "Financial Instruments" and IFRS 7, "Financial Instruments: Disclosures". The amendments clarify the timing of recognition and derecognition for a financial asset or financial liability, including clarifying that a financial liability is derecognized on the settlement date. In addition to these clarifications, the amendments introduce an accounting policy choice to derecognize financial liabilities settled using an electronic payment system before the settlement date, if specific conditions are met. Also included in the amendments,

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

are clarifications regarding the classification of financial assets, including those with features linked to environmental, social and corporate governance. Under the amendments, additional disclosures are required for financial instruments with contingent features and investments in equity instruments classified at fair value through other comprehensive income. These amendments are effective for annual reporting periods beginning on or after January 1, 2026. Early adoption is permitted, with an option to early adopt only the amendments to the classification of financial assets. The Company is assessing the impacts of the IFRS 9 and IFRS 7 amendments on its consolidated financial statements.

IFRS 18

On April 9, 2024, the IASB issued IFRS 18 "Presentation and Disclosures in Financial Statements". The objective of the new standard is to set out requirements for the presentation and disclosure of information in general purpose financial statements to help ensure they provide relevant information that faithfully represents an entity's assets, liabilities, equity, income and expenses. The new standard is effective for reporting periods beginning on or after January 1, 2027. The Company is assessing the impacts of IFRS 18 on its consolidated financial statements.

4. Critical Accounting Estimates and Judgments

The preparation of interim financial statements in accordance with IFRS Accounting Standards requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

In preparing these condensed interim consolidated financial statements, the significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the December 31, 2024 audited annual consolidated financial statements.

5. Revenue

The following table shows the details of revenues for the three and nine months ended September 30, 2025 and 2024:

	Three months ended		Nine months ended	
	September 30,	September 30,	September 30,	September 30,
	2025	2024	2025	2024
		Restated		Restated
Public insured	114,352	77,214	327,950	226,380
Non-public and other	200,514	141,367	566,737	410,700
Patient Services	314,866	218,581	894,687	637,080
SaaS and Technology Services	49,733	15,554	120,722	47,850
Total Revenue	364,599	234,135	1,015,409	684,930

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

6. General and Administrative Expenses

The following table shows the details of general and administrative expenses for the three and nine months ended September 30, 2025 and 2024:

	Three months ended		Nine months ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Salaries and benefits	54,919	36,446	156,148	109,542
Marketing and promotion	23,095	23,374	69,505	62,315
Professional and consulting fees	8,924	5,142	20,461	15,648
Office expenses	8,129	6,336	22,870	18,748
Other	8,895	5,477	24,135	15,487
	103,962	76,775	293,119	221,740

7. Interest Income and Expense

The following table shows a breakdown of interest income and interest expense for the three and nine months ended September 30, 2025 and 2024:

	Three months ended		Nine months ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Interest accretion on subleases	30	161	101	469
Interest income on cash and cash equivalent and others	312	94	1,223	303
Interest income	342	255	1,324	772
Interest on loans and borrowings	7,005	5,404	18,477	17,025
Interest on convertible debentures	4,014	2,444	10,062	7,079
Interest on redeemable preferred shares (Note 15(c))	1,986	-	5,747	-
Interest accretion on lease liability	1,152	981	3,188	2,837
Amortization of deferred financing fees	318	73	960	857
Accretion of discount on deferred acquisition costs (Note 14(a))	1,753	201	2,109	535
Interest expense	16,228	9,103	40,543	28,333

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

8. Time-based Earnout Expense

The following table shows a breakdown of time-based earnout expense for the three and nine months ended September 30, 2025 and 2024:

	Three months ended		Nine months ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Time-based earnout expense	69	1,829	1,792	4,936
(Gain) loss on settlement of certain deferred acquisition cost and time-based earnout liabilities via shares	(10)	-	(1,931)	258
Loss (gain) on revaluation of deferred acquisition cost liability	1,524	-	7,074	(1,238)
	1,583	1,829	6,935	3,956

9. Accounts and Other Receivables, and Contract assets and liabilities

(a) Accounts and other receivables

The following table shows the details of the Company's accounts and other receivables as at September 30, 2025 and December 31, 2024:

	September 30, 2025	December 31, 2024
Accounts Receivable – gross	205,415	188,744
Less: Expected credit losses	(6,906)	(4,239)
	198,509	184,505
Accounts Receivable – gross		
Canadian Patient Services – Primary	18,388	15,034
Canadian Patient Services – Specialized – MyHealth	15,216	13,322
U.S. Patient Services – Primary – Circle Medical	6,269	11,936
U.S. Patient Services – Primary – WISP	1,488	1,300
U.S. Patient Services – Primary – CRH Medical	88,532	100,284
U.S. Patient Services – Primary – Provider Staffing	25,528	19,073
HEALWELL	25,796	-
SaaS and Technology Services	21,102	20,214
Other receivables	3,096	7,581
	205,415	188,744

The Company evaluates credit losses on a periodic basis based on the aging and collectability of its accounts receivable. As at September 30, 2025, the Company recognized expected credit losses of \$6,906 (December 31, 2024 - \$4,239), which have been recorded as a reduction of accounts receivable. The expected lifetime credit loss provision for trade receivables is based on historical counterparty default rates and is adjusted for relevant forward-looking information as required.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

In February 2024, CRH Medical Corporation's ("CRH") former third-party billing service provider experienced a cyberattack and system shutdown and was unable to process billings or payments from CRH's customers for an extended period of time. This resulted in an increase in CRH's accounts receivable over several months in 2024. The billing service provider subsequently restored claims submission and payment functionality and as of August 2024, CRH resumed regular processes. CRH subsequently collected \$79,452 up to December 31, 2024 and \$30,272 during the nine months ended September 30, 2025, and offset the payments against accounts receivable. During the year ended December 31, 2024, the Company received cash advance payments of \$165,441 directly from the billing service provider under a temporary funding assistance program to provide funding relief to CRH for the delayed collections and during the nine months ended September 30, 2025, the Company repaid \$91,317 of the advances from the billing service provider. The advance payments have been recognized as advances payable on the Company's consolidated statements of financial position and have not been offset against accounts receivable (Note 14(c)).

(b) Contracts assets and liabilities

Each customer is billed in accordance with the terms of the contractual arrangement that it has entered into with the Company. This means that customer billing and payments are not always aligned with revenue recognition. Contract assets arise when revenue is recognized prior to a customer being billed. Contract liabilities arise when a customer is billed in advance of revenue being earned.

	September 30, 2025	December 31, 2024
Contract assets	20,436	-
Contract liabilities	(21,783)	-

10. Financial Assets at Fair Value Through Profit and Loss

The following table provides the carrying values of the Company's investments in financial assets measured at fair value through profit and loss as at September 30, 2025 and December 31, 2024:

		September 30, 2025	December 31, 2024
HEALWELL	(a)	-	147,824
Tali.ai		2,154	2,154
Phelix		2,859	2,859
Anesthesia RCM	(b)	-	2,901
Fund holding X.AI Securities		4,606	-
Future Vault Securities		350	-
Abstractive Health		348	-
Others		4,400	2,738
		14,717	158,476

Financial asset investments include debt, equity and derivative instruments and are measured at fair value through profit and loss (FVPL) in accordance with IFRS 9. The Company uses various fair value techniques to estimate the fair value of these investments. During the nine months ended September 30, 2025, the Company recognized fair value losses of \$22,795 made up of \$35,235 loss on the HEALWELL financial assets offset by \$11,444 of remeasurement gain as part of its previously held equity

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

interest in HEALWELL at its acquisition-date fair value and fair value gain of \$996 on all other financial assets (nine months ended September 30, 2024 – fair value gains of \$53,192 on the HEALWELL financial assets, made up of \$17,010 on the convertible debentures, \$14,440 on the warrants and \$21,742 on the call option).

(a) Investment in HEALWELL AI Inc. ("HEALWELL")

On October 1, 2023, as part of a strategic alliance and investment transaction with HEALWELL, the Company acquired an interest in HEALWELL in the form of convertible debentures, warrants and a call option.

During the three months ended March 31, 2025 prior to obtaining control of HEALWELL, the Company recognized fair value losses of \$35,235 on the HEALWELL financial assets (\$14,975 on the convertible debentures, \$5,544 on the warrants and \$14,716 on the call option) and accrued interest income of \$94 on the convertible debentures.

On March 26, 2025, the Company exercised 20,312,500 HEALWELL share purchase warrants for total consideration of \$4,375 and converted all outstanding HEALWELL convertible debentures and interest accrued thereon. The fair value of the HEALWELL Class A Subordinate Shares acquired upon exercise and conversion of these instruments of \$70,550 was reclassified to investments accounted for using the equity method on the Company's consolidated statement of financial position as of March 26, 2025.

On April 1, 2025, the Company and the HEALWELL founders amended the terms of the conditional call option held by the Company to acquire up to 30,800,000 Class A Subordinate Voting Shares of HEALWELL at \$0.125 per share and 30,800,000 Class B Multiple Voting Shares of HEALWELL at \$0.0001 per share. The amendment removed the trigger condition requiring HEALWELL to achieve positive consolidated Adjusted EBITDA for two consecutive quarters and replaced it with the closing of HEALWELL's acquisition of Orion Health Holdings Limited ("Orion Health"). On April 1, 2025, HEALWELL closed the acquisition of Orion Health making the call option exercisable, and the Company exercised the call option to acquire 30,800,000 Class A Subordinate Voting Shares and 30,800,000 Class B Multiple Voting Shares of HEALWELL for total consideration of \$3,853.

Following these transactions, as at April 1, 2025, the Company held 97,223,161 Class A Subordinate Shares and 30,800,000 Class B Multiple Voting Shares of HEALWELL, representing a 37% economic interest and a 69% voting interest in HEALWELL on a non-diluted basis. As a result of having majority voting control and an ability to nominate the majority of HEALWELL's Board of Directors, the Company obtained control of HEALWELL under IFRS Accounting Standards, and accordingly, began consolidating the financial results of HEALWELL as a subsidiary of the Company effective April 1, 2025 (Note 19).

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(b) Investment in an anesthesia revenue cycle management organization ("Anesthesia RCM")

Effective January 1, 2025, CRH entered into a unit redemption and release agreement with Anesthesia RCM, whereby Anesthesia RCM redeemed all shares held by CRH. In exchange, Anesthesia RCM agreed to reduce its aggregate fees charged to CRH and its affiliates in the state of Florida by 1% over a five-year period. The initial asset was recognized at \$2,898 being the estimated fair value of the future fee reductions and has been recorded in other assets, current and non-current and the investment has been derecognized on the Company's consolidated statement of financial position.

11. Investments Accounted for Using the Equity Method

		September 30, 2025	December 31, 2024
HEALWELL	(a)	-	11,800
Pillway		3,066	3,510
Others		39	-
		3,105	15,310

(a) Investment in HEALWELL

On January 21, 2025, the Company subscribed for 500,000 subscription receipts in HEALWELL for an aggregate subscription price of \$1,000 which entitled the Company to receive, upon satisfaction of certain release conditions, 500,000 Class A Subordinate Voting shares of HEALWELL and 250,000 share purchase warrants with each warrant exercisable into one Class A Subordinate Voting share at \$2.50 per share for a period of 36 months. On April 1, 2025, the release conditions were satisfied and the Company received the shares and share purchase warrants in accordance with the terms of the subscription agreement.

On March 26, 2025, the Company exercised 20,312,500 HEALWELL share purchase warrants for total consideration of \$4,375 and converted all outstanding HEALWELL convertible debentures and interest accrued thereon, and reclassified the fair value of the HEALWELL Class A Subordinate Voting Shares acquired in these transactions of \$70,550 to investments accounted for using the equity method as of March 26, 2025.

On April 1, 2025, the Company exercised its call option to acquire 30,800,000 Class A Subordinate Voting Shares and 30,800,000 Class B Multiple Voting Shares of HEALWELL, increasing the Company's economic interest to 37% and voting interest to 69% resulting in the acquisition of control of HEALWELL (Note 10(a)) (December 31, 2024 – economic interest of 13% and voting interest of 14%). The equity method investment in HEALWELL was derecognized and HEALWELL became a consolidated subsidiary.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

12. Intangible Assets and Goodwill

	Customer relationships	Technology	Brands	Licenses	Intangibles Total	Goodwill
COST						
Balance at December 31, 2023	441,445	30,001	14,824	181,761	668,031	508,061
Acquired via asset acquisitions (Note 19)	20,185	-	-	-	20,185	-
Acquired via business combination (Note 19)	9,023	2,993	-	-	12,016	28,332
Internally generated intangible assets	-	9,821	-	-	9,821	-
Exchange difference on foreign currency translation and other	46,011	1,068	631	-	47,710	28,724
Balance at December 31, 2024	516,664	43,883	15,455	181,761	757,763	565,117
Acquired via business combination (Note 19)	132,220	58,359	33,122	-	223,701	193,481
Acquired via asset acquisitions (Note 19)	14,628	-	-	-	14,628	-
Internally generated intangible assets	-	11,489	-	-	11,489	-
Disposal	(2,287)	-	-	-	(2,287)	-
Impairment	-	-	-	-	-	(10,506)
Exchange difference on foreign currency translation and other	(23,412)	(963)	(596)	-	(24,971)	(14,132)
Balance at September 30, 2025	637,813	112,768	47,981	181,761	980,323	733,960
ACCUMULATED AMORTIZATION						
Balance at December 31, 2023	(102,911)	(7,080)	(2,840)	-	(112,831)	-
Amortization for the period	(46,014)	(3,182)	(997)	-	(50,193)	-
Exchange difference on foreign currency translation and other	(19,924)	(719)	(134)	-	(20,777)	-
Balance at December 31, 2024	(168,849)	(10,981)	(3,971)	-	(183,801)	-
Amortization for the period	(39,604)	(8,597)	(1,760)	-	(49,961)	-
Disposal	2,085	-	-	-	2,085	-
Exchange difference on foreign currency translation and other	11,791	73	-	-	11,864	-
Balance at September 30, 2025	(194,577)	(19,505)	(5,731)	-	(219,813)	-
NET CARRYING AMOUNTS						
As at December 31, 2024	347,815	32,902	11,484	181,761	573,962	565,117
As at September 30, 2025	443,236	93,263	42,250	181,761	760,510	733,960

During the nine months ended September, 30, 2025, the Company acquired \$223,701 of intangible assets via business combinations, comprising customer relationships, technology, and brands.

The customer relationship assets were valued using key inputs such as revenue growth rates, customer attrition rates, and a discount rate determined using the capital asset pricing model, and have an estimated useful life of ten years.

The technology was valued using assumptions on royalty rates, a technology migration factor, and a market-based discount rate, with an estimated useful life of ten years.

The brands were valued using the relief-from-royalty method, incorporating assumptions on royalty rates benchmarked to comparable market transactions, forecast revenue attributable to the brand, and a market-based discount rate, with an estimated useful life of ten years.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

An impairment charge of \$10,506 was recognized during the three months ended September 30, 2025 in HEALWELL. The impairment has been fully allocated against goodwill. The impairment charge has been recorded within operating expenses in the consolidated statement of income (loss) and comprehensive income (loss).

Goodwill is monitored by management at the level of the following CGU(s) or group of CGUs, with the allocation summarized below:

Carrying value of goodwill in CGU or group of CGUs	September 30, 2025
Primary Care	131,054
WDC	45,136
CRH Medical	275,451
CRH Provider Staffing	28,089
Circle Medical	15,481
WISP	41,691
HEALWELL	115,991
WELLSTAR and other	64,938
CYBERWELL	16,129
	733,960

13. Deferred Revenue

	September 30, 2025	December 31, 2024
Balance, beginning of period	59,450	6,903
Acquired via business combinations (Note 19)	3,638	-
Billings	40,196	82,479
Revenue recognized	(56,989)	(32,567)
Exchange difference	(2,126)	2,635
Balance, end of period	44,169	59,450
Current	44,169	59,450
Non-current	-	-
Balance, end of period	44,169	59,450

Deferred revenue represents cash received by the Company from customers for which either goods or services have not yet been delivered, or the criteria for revenue recognition under IFRS 15, "Revenue from Contracts with Customers", have not been fully met.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

As at September 30, 2025, deferred revenue includes the following amounts billed:

	September 30, 2025	December 31, 2024
U.S. Patient Services – Primary – Circle Medical	33,988	53,949
Other operating segments	10,181	5,501
	44,169	59,450

During the nine months ended September 30, 2025, Circle Medical received cash of \$14,846 from customers for patient services rendered and recognized it as deferred revenue as at September 30, 2025 as it has not met criteria related to the right to payment under IFRS 15, "Revenue from Contracts with Customers" (nine months ended September 30, 2024 – \$35,291) (Note 2(c)).

14. Deferred Acquisition Costs and Other Liabilities

(a) Deferred acquisition costs

Deferred acquisition costs are liabilities for time-based earnout payments that are treated as purchase consideration for business combinations and asset acquisitions (Note 19).

	September 30, 2025	December 31, 2024
Current	25,587	14,585
Non-current	35,124	16,354
	60,711	30,939

Balance at December 31, 2023	37,071
Additions via business combinations and asset acquisitions (Note 19)	4,530
Accretion of discount	735
Settlement in cash	(7,542)
Settlement in common shares	(6,899)
Loss on settlement via shares	175
Loss on revaluation included in time-based earnout expenses	3,029
Exchange difference and other	(160)
Balance at December 31, 2024	30,939
Additions via business combinations and asset acquisitions (Note 19)	36,571
Accretion of discount	2,109
Settlement in cash	(2,717)
Settlement in common shares	(11,285)
Gain on settlement via shares	(1,931)
Loss on revaluation included in time-based earnout expenses	7,074
Exchange difference and other	(49)
Balance at September 30, 2025	60,711

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(b) Other liabilities

	September 30, 2025	December 31, 2024
<i>Current:</i>		
Payroll liabilities and others	28,173	18,680
Time-based earnouts	3,967	6,040
Income tax payable	6,301	661
Working capital holdback	4,296	2,601
	42,737	27,982
<i>Non-current:</i>		
Others	2,237	2,292

(c) Advances payable

	September 30, 2025	December 31, 2024
Balance, beginning of period	165,441	-
Cash advance payments received	-	157,170
Cash advance payment repaid	(91,317)	-
Exchange difference	(4,597)	8,271
Balance, end of period	69,527	165,441
Current	69,527	165,441
Non-current	-	-
Balance, end of period	69,527	165,441

The Company has received advance payments under a temporary funding assistance program to provide funding relief to CRH after the billing service provider experienced a cybersecurity attack and system shutdown and was unable to process billings or payments from CRH's customers. Amounts provided under this program are subject to repayment within 30 days of notification of repayment and have been recorded as advances payable on the Company's consolidated statements of financial position.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

15. Loans and Borrowings, Convertible Debentures and Redeemable Preferred Shares

(a) Syndicated credit facilities

	September 30, 2025	December 31, 2024
CRH syndicated credit facility with JPM:		
Revolving loan	151,033	124,670
Term loan	69,866	75,183
WHCC and MyHealth syndicated credit facility with RBC:		
Revolving loan	86,200	50,700
Term loan	40,000	41,875
HEALWELL syndicated credit facility with BNS:		
Revolving loan	29,500	-
Term loan	19,500	-
Other loans and borrowings	2,137	387
Less: Financing fees	(2,626)	(2,550)
Total Loans and Borrowings	395,610	290,265
Current portion	6,449	5,534
Non-current portion	389,161	284,731
Total Loans and Borrowings	395,610	290,265

- (i) WELL Health Clinics Canada Inc. ("WHCC") and MyHealth Partners Inc. ("MyHealth") syndicated credit facility with Royal Bank of Canada ("RBC"):

The Company, through its wholly-owned subsidiaries, WHCC and MyHealth, holds a syndicated five-year revolving credit facility and a term loan with RBC as syndicate lead which provides up to a \$90,000 revolving facility, a \$50,000 term loan facility and access to an accordion feature that increases the amount of the credit available to the Company by \$60,000. On July 7, 2025, the Company exercised the accordion and increased the revolving facility to \$149,391 and extended the maturity date to July 15, 2027. All other terms remain unchanged.

- (ii) HEALWELL credit facility with The Bank of Nova Scotia ("BNS")

HEALWELL holds a credit agreement with a syndicate of lenders led by BNS, including senior secured credit facilities consisting of a \$30,000 revolving credit facility (including a \$5,000 swingline tranche), a \$20,000 non-revolving term facility and a \$1,000 credit card facility. The credit facilities mature on March 4, 2028. The term loan is repayable in quarterly principal installments of \$250, with mandatory prepayments under specified conditions. Interest is calculated based on a tiered pricing grid tied to Orion Health's leverage ratio, with rates based on Prime, US Base Rate, CORRA, or SOFR. The facilities are secured by a first-ranking charge over all present and after-acquired property of Orion Health and its direct and indirect parents and subsidiaries. The agreement includes an accordion feature allowing for an increase in the revolving facility by up to \$25,000, subject to lender consent.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(iii) Financial covenants

The Company's syndicated credit facilities with loans outstanding as at September 30, 2025 of \$220,899 with JPMorgan Chase Bank, N.A. ("JPM"), \$126,200 with RBC, and \$49,000 with BNS are subject to financial covenants based on the consolidated financial results of CRH, WHCC and MyHealth, and Orion Health. Financial covenants include maintenance of certain leverage ratios, fixed charge coverage ratios and guarantor and capital expenditure thresholds and compliance is evaluated quarterly as of March 31, June 30, September 30 and December 31 of each year. The Company was in compliance with all financial covenants and other terms and conditions under its syndicated credit facilities as of September 30, 2025.

(iv) Minimum principal repayments

Total minimum principal repayments under the syndicated credit facilities were as follows as at September 30, 2025:

	CRH (JPM)	WCC and MyHealth (RBC)	HEALWELL (BNS)
Remainder of 2025	957	625	250
2026	3,828	2,500	1,000
2027	216,114	123,075	1,000
2028	-	-	46,750
	220,899	126,200	49,000

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(b) Convertible debentures and derivative liability

	September 30, 2025	December 31, 2024
Current	28,713	3,850
Non-current	60,604	51,244
	89,317	55,094

	Convertible debentures	Derivative liability
Balance as of December 31, 2023	49,421	-
Interest accretion	9,523	-
Interest paid	(3,850)	-
Balance as of December 31, 2024	55,094	-
Acquired via business acquisition (Note 19(a))	21,496	7,046
Interest accretion (Note 7)	10,062	-
Interest paid	(2,675)	-
Change in fair value of derivative liability	-	(1,642)
Conversion into subsidiary's shares	(64)	-
Balance as of September 30, 2025	83,913	5,404
Current	23,309	5,404
Non-current	60,604	-

(i) HEALWELL debenture payable

In connection with the Orion Health acquisition, HEALWELL completed a series of financing transactions comprising a \$30,000 convertible debenture offering, a \$25,500 equity offering, and a \$50,000 senior credit facility. The equity financing and convertible debenture offering were completed on January 21, 2025, and HEALWELL issued 30,000 subscription receipts with an aggregate principal amount of \$30,000 at a discounted purchase price of \$910 per receipt. Each receipt entitles the holder to \$1,000 principal amount of convertible debentures (the "2025 Debentures"), bearing interest at 10% annually, payable semi-annually on June 30 and December 31, beginning after issuance. The 2025 Debentures mature on December 31, 2029.

The principal amount of the 2025 Debentures is convertible into HEALWELL Class A Subordinate Voting Shares at a fixed conversion price of \$2.40 per share, subject to standard anti-dilution adjustments. Holders may convert at any time prior to maturity, and accrued interest is payable in cash upon conversion. HEALWELL may redeem the 2025 Debentures, in whole or in part, at 110% of principal plus accrued interest, at any time between December 31, 2027 and December 31, 2029. In the event of a change of control, HEALWELL is required to repurchase the 2025 Debentures.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Additionally, HEALWELL holds a mandatory conversion right whereby, if the 10-day volume-weighted average price ("VWAP") of HEALWELL Class A Subordinate Voting Shares exceeds \$3.85 at any time after 10 trading days following four months and one day from the issuance date, it may require holders to convert their 2025 Debentures into HEALWELL Class A Subordinate Voting Shares at the \$2.40 conversion price, with accrued and unpaid interest payable in cash.

The 2025 Debentures are a hybrid financial instrument comprising liability, the derivative liability assigned to the holder conversion option, and equity components. On initial recognition, the transaction price was allocated to the liability and derivative liability components based on their standalone fair values, with any residual assigned to equity. Post-recognition, the liability is measured at amortized cost, the derivative liability at fair value through profit or loss, and the equity component is not subsequently remeasured.

(c) Redeemable preferred shares

On December 11, 2024, the Company's subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR") issued Series A Preferred Shares for gross proceeds of \$50,378 (net proceeds of \$47,645 after issuance costs). The preferred shares are redeemable at the option of the holders for a fixed return at any time after December 31, 2026. If a holder exercises the redemption option, the Company has a call right to purchase the preferred shares and the holder has a put right to require the Company to purchase the preferred shares at a price equal to the holder's redemption price. The preferred shares automatically convert into a variable number of subordinate voting shares of WELLSTAR at a discounted price upon a qualifying initial public offering or reverse takeover public listing, or alternative liquidity transaction. The preferred shares are entitled to quarterly dividends commencing March 31, 2026 at an increasing rate over time. The dividends will accrue as notional preferred shares until the occurrence of a liquidity event, redemption or other liquidation event in accordance with the terms of the preferred shares. The preferred shares have been classified as a liability in the consolidated statements of financial position of WELLSTAR and the Company due to the redemption feature at the option of the holders and other terms that result in the instrument meeting the definition of a financial liability. The financial liability was initially recognized at \$47,645, being fair value less transaction costs and is subsequently being measured at amortized cost using the effective interest rate method. For the nine months ended September 30, 2025, the Company recognized interest expense of \$5,747 on the redeemable preferred shares liability (nine months ended September 30, 2024 - \$nil).

	September 30, 2025	December 31, 2024
Balance, beginning of period	48,054	-
Proceeds from issuance	-	50,378
Issuance costs	(57)	(2,733)
Interest accretion	5,747	409
Balance, end of period	53,744	48,054

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

16. Share Capital

(a) Authorized

Unlimited common shares without par value.

(b) Issued common shares

As at September 30, 2025, the issued share capital consisted of 253,894,045 (December 31, 2024 – 249,091,940) common shares.

(c) Normal course issuer bid ("NCIB")

(i) 2024 NCIB

On September 6, 2024, the Company received approval from the TSX for a renewal of the NCIB that expired on September 4, 2024. Under the renewed 2024 NCIB, the Company could have acquired up to an aggregate of 6,154,501 common shares from September 10, 2024 to September 9, 2025. In accordance with TSX rules, daily purchases made by the Company on the TSX could not have exceeded 209,016 common shares, subject to certain prescribed exemptions, being 25% of the average daily trading volume over the preceding nine calendar months of 836,067 common shares. On January 16, 2025, the 2024 NCIB program was cancelled due to the TSX approved broker deciding to wind down its operations and cease executing trade orders. As of January 15, 2025, 127,000 common shares were purchased under the prior NCIB, and 298,500 common shares were purchased under the 2024 NCIB.

(ii) 2025 NCIB

On May 20, 2025, the Company received early renewal approval of its NCIB that was set to expire on September 9, 2025 from the TSX. Under the renewed NCIB, the Company may acquire up to an aggregate of 6,326,417 common shares from May 20, 2025 to May 19, 2026. In accordance with TSX rules, daily purchases made by the Company on the TSX cannot exceed 284,830 common shares, subject to certain prescribed exemptions, being 25% of the average daily trading volume over the preceding nine calendar months of 1,139,321 common shares. As of September 30, 2025, 241,400 shares have been purchased under the 2025 NCIB. As of November 5, 2025, 297,100 shares have been purchased under the 2025 NCIB.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(d) Options to purchase common shares

(i) Movement in stock options

The changes in stock options during the nine months ended September 30, 2025 and the year ended December 31, 2024 were as follows:

	September 30, 2025		December 31, 2024	
	Number of options	Weighted average exercise price \$	Number of options	Weighted average exercise price \$
Balance outstanding, beginning of year	365,500	2.89	1,980,873	1.79
Options exercised	(140,500)	2.46	(1,615,373)	1.53
Balance outstanding, end of period	225,000	3.16	365,500	2.89

During nine months ended September 30, 2025 and 2024, the Company recognized share-based payments of \$499 and \$582 respectively, relating to stock options in the condensed interim consolidated statements of income (loss).

(ii) Stock options outstanding at the end of the period

The following table summarizes information relating to outstanding and exercisable stock options of the Company as at September 30, 2025:

Exercise price \$	Options outstanding	Options exercisable	Weighted average remaining contractual life (years)
3.06	100,000	75,000	2.00
3.25	125,000	125,000	0.25
	225,000	200,000	1.03

The weighted average exercise price of options exercisable as at September 30, 2025 was \$3.18 (December 31, 2024 - \$2.87).

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(e) Restricted share units ("RSUs")

The changes in RSUs during the nine months ended September 30, 2025 and the year ended December 31, 2024 were as follows:

	September 30, 2025	December 31, 2024
	Number of RSUs	Number of RSUs
Balance outstanding, beginning of year	3,370,902	5,065,068
Units granted	988,834	1,595,437
Units vested and shares issued	(1,606,980)	(2,737,544)
Units forfeited	(54,396)	(552,059)
Balance outstanding, end of period	2,698,360	3,370,902

During the nine months ended September 30, 2025 and 2024, the Company recognized share-based payments of \$3,760 and \$7,226, respectively, relating to RSUs in the condensed interim consolidated statements of income (loss).

(f) Performance share units ("PSUs")

The changes in PSUs during the nine months ended September 30, 2025 and the year ended December 31, 2024 were as follows:

	September 30, 2025	December 31, 2024
	Number of PSUs	Number of PSUs
Balance outstanding, beginning of year	2,460,449	3,401,645
Units granted	1,250,800	801,828
Units vested and shares issued	(1,116,650)	(1,389,361)
Units forfeited	(46,862)	(353,663)
Balance outstanding, end of period	2,547,737	2,460,449

During the nine months ended September 30, 2025 and 2024, the Company recognized share-based payments of \$3,168 and \$4,575, respectively, relating to PSUs in the condensed interim consolidated statements of income (loss).

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(g) Share-based awards of subsidiary, HEALWELL

See below the information regarding the Company's subsidiary, HEALWELL, as of September 30, 2025:

(i) Stock options

	September 30, 2025	
	Number of options	Weighted average exercise price \$
Balance outstanding, April 1, 2025	2,597,000	1.30
Options granted	100,000	1.42
Options settled	(6,250)	0.69
Balance outstanding, end of period	2,690,750	1.30

(ii) DSUs (Deferred share units), RSUs and PSUs

Net outstanding share-based payments by type		
September 30, 2025	No. of shares	Vested
PSUs		
Grants in 2023	858,334	108,332
Grants in 2024	297,917	10,416
Grants in 2025	4,955,988	59,476
Total PSUs	6,112,239	178,224
RSUs		
Grants in 2023	971,667	174,998
Grants in 2024	1,680,065	812,082
Grants in 2025	5,806,325	184,359
Total RSUs	8,458,057	1,171,439
DSUs		
Grants in 2024	43,947	43,947
Total DSUs	43,947	43,947
Total number of shares	14,614,243	1,393,610

For the period April 1, 2025 to September 30, 2025, the Company recognized share-based payments of \$6,802, relating to HEALWELL's share-based awards in the condensed interim consolidated statements of income (loss).

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

17. Related Party Balances and Transactions

(a) Related party balances and transactions with management

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel consists of the Company's Board of Directors and certain members of the senior executive team. Key management personnel are the Chief Executive Officer ("CEO"), the Chief Financial Officer ("CFO") and the Chief Operating Officer ("COO"). The remuneration of the Company's key management personnel during the three and nine months ended September 30, 2025 and 2024 was as follows:

	Three months ended		Nine months ended	
	September 30,	September 30,	September 30,	September 30,
	2025	2024	2025	2024
Salaries and bonuses	323	260	1,168	770
Directors' fees	100	60	360	180
Share-based payments	716	776	1,289	4,002
	1,139	1,096	2,817	4,952

During the nine months ended September 30, 2025, the Company granted 379,629 RSUs (141,806 to the CEO, 7,878 to the CFO, 9,359 to the COO and 220,586 to the members of the Board of Directors), and 288,054 PSUs (236,343 to the CEO, 23,634 to the CFO, and 28,077 to the COO). During the nine months ended September 30, 2024, the Company granted 481,573 RSUs (197,367 to the CEO, 39,473 to the CFO, 39,473 to the COO and 205,260 to the Board of Directors), and 78,946 PSUs (39,473 to the CFO, and 39,473 to the COO).

Included in other current assets as at September 30, 2025 and December 31, 2024 is \$12,164 (\$7,099 from the CEO, \$2,793 from the CFO, and \$2,272 from the COO) and \$11,804 (\$7,099 from the CEO, \$2,433 from the CFO, and \$2,272 from the COO), respectively, of receivables from related parties. These receivables were related to payroll taxes on stock issuance with respect to equity and option exercises for the related parties. They are interest bearing at interest rates as prescribed by Canada Revenue Agency, payable on demand with no specified repayment terms. The Company has full recourse to assets of the related parties if they were unable or unwilling to pay.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(b) Related party balances and transactions with HEALWELL

Effective April 1, 2025, the Company controls and consolidates HEALWELL, and any transactions and balances between WELL and HEALWELL subsequent to April 1, 2025 have been eliminated on consolidation. The following balances outstanding with HEALWELL as of December 31, 2024 were prior to control and consolidation:

	September 30, 2025	December 31, 2024
Included in accounts and other receivables:		
Accounts receivable	-	167
Convertible promissory note receivable, including accrued interest	-	5,300
Other receivable	-	1,134
Deferred acquisition costs	-	642
Working capital holdback receivable	-	606
	-	7,849
Included in other current liabilities:		
Working capital holdback payable	-	150
Other current liabilities	-	154
	-	304

On February 1, 2024, in connection with its sale of Intrahealth to HEALWELL, the Company received a convertible promissory note from HEALWELL for a portion of the purchase price in the principal amount of \$5,000. The promissory note bore interest at a rate of 18% per annum and was repayable over the 10 months following the closing date in either cash or shares. Effective November 1, 2024, the promissory note was amended to change the interest rate to 8% per annum and to extend the maturity date to March 31, 2026. The interest will be payable on maturity of the respective promissory notes. The outstanding amount may be converted into Class A Subordinate Voting Shares of HEALWELL at the option of the Company. As of December 31, 2024, the Company recognized receivables due from HEALWELL of \$5,300 for the convertible promissory note including accrued interest, \$642 for deferred acquisition costs, and \$606 for a holdback in relation to the sale of Intrahealth to HEALWELL.

See Note 11(a) for other transactions between the Company and HEALWELL.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

18. Segment Reporting

The Company is organized into operating segments based on its product and service offerings. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker who is the CEO. The Company has eight reportable segments as shown below that are grouped into four key business units: Canadian Patient Services, WELL Health USA Patient and Provider Services, SaaS and Technology Services and HEALWELL.

Reportable Segment	Operations
Canadian Patient Services – Primary WELL Health Medical Centres or WMC	Primary care and allied health clinic operations in Canada
Canadian Patient Services – Specialized MyHealth Also known as WELL Health Diagnostic Centres or WDC	Specialty care and accredited diagnostic health services from WDC
WELL Health USA Patient and Provider Services - Primary Circle Medical	US primary care telehealth operations from Circle Medical
- Primary WISP	US primary care operations from WISP
- Specialized CRH Medical	Specialized care gastroenterology anesthesia services
- Specialized Provider Staffing	Medical recruitment and staffing services
SaaS and Technology Services	Aggregation of electronic medical records ("EMR"), billing and revenue cycle management solutions, digital applications, and cybersecurity operating segment
HEALWELL	AI and Data Sciences, Healthcare Software, Clinical Research and Patient Services offerings

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Three months ended September 30, 2025

	< - Canadian Patient Services - >			< - WELL Health USA Patient and Provider Services - >									
	Primary - WMC	Specialized - WDC	Total	Primary - Circle Medical	Primary - WISP	Specialized - CRH Medical	Specialized - Provider Staffing	Total	SAAS and Technology Services	HEALWELL	Total - All segments	Corporate / Elimination	Grand total
Total segment revenue	71,817	38,678	110,495	41,960	30,340	72,510	53,992	198,802	21,001	38,123	368,421	4,910	373,331
Inter-segment revenue	(270)	(171)	(441)	-	-	-	(1,415)	(1,415)	(1,715)	(251)	(3,822)	(4,910)	(8,732)
Revenue from external customers	71,547	38,507	110,054	41,960	30,340	72,510	52,577	197,387	19,286	37,872	364,599	-	364,599
Cost of sales	(49,148)	(14,730)	(63,878)	(10,434)	(8,069)	(44,681)	(47,889)	(111,073)	(3,031)	(19,276)	(197,258)	(1,570)	(198,828)
Salaries and benefits	(8,954)	(10,845)	(19,799)	(4,304)	(3,190)	(4,616)	(768)	(12,878)	(6,945)	(11,905)	(51,527)	(3,392)	(54,919)
Marketing and promotion	(330)	(256)	(586)	(2,584)	(16,264)	(225)	(61)	(19,134)	(140)	(2,949)	(22,809)	(286)	(23,095)
Other G&A	(7,542)	(4,102)	(11,644)	(2,305)	(1,517)	(3,999)	(187)	(8,008)	(2,330)	(2,344)	(24,326)	(3,514)	(27,840)
Operating expenses	(65,974)	(29,933)	(95,907)	(19,627)	(29,040)	(53,521)	(48,905)	(151,093)	(12,446)	(36,474)	(295,920)	(8,762)	(304,682)
Adjusted EBITDA	5,573	8,574	14,147	22,333	1,300	18,989	3,672	46,294	6,840	1,398	68,679		

Three months ended September 30, 2024 ("Restated", refer to Note 2 (c))

	< - Canadian Patient Services - >			< - WELL Health USA Patient and Provider Services - >									
	Primary - WMC	Specialized - WDC	Total	Primary - Circle Medical	Primary - WISP	Specialized - CRH Medical	Specialized - Provider Staffing	Total	SAAS and Technology Services	HEALWELL	Total - All segments	Corporate / Elimination	Grand total
Total segment revenue	47,847	30,198	78,045	19,057	26,869	63,197	32,123	141,246	16,594	-	235,885	3,919	239,804
Inter-segment revenue	(56)	-	(56)	-	-	(51)	(603)	(654)	(1,040)	-	(1,750)	(3,919)	(5,669)
Revenue from external customers	47,791	30,198	77,989	19,057	26,869	63,146	31,520	140,592	15,554	-	234,135	-	234,135
Cost of sales	(32,947)	(11,320)	(44,267)	(16,170)	(6,884)	(38,738)	(28,256)	(90,048)	(5,882)	-	(140,197)	710	(139,487)
Salaries and benefits	(7,141)	(8,853)	(15,994)	(5,219)	(2,868)	(4,808)	(146)	(13,041)	(4,737)	-	(33,772)	(2,674)	(36,446)
Marketing and promotion	(231)	(166)	(397)	(7,824)	(14,506)	(238)	(32)	(22,600)	(148)	-	(23,145)	(229)	(23,374)
Other G&A	(4,545)	(3,135)	(7,681)	(4,881)	(1,149)	(1,815)	(592)	(8,437)	(401)	-	(16,519)	(3,175)	(19,694)
Operating expenses	(44,865)	(23,474)	(68,339)	(34,094)	(25,407)	(45,599)	(29,026)	(134,126)	(11,168)	-	(213,633)	(5,368)	(219,001)
Adjusted EBITDA	2,926	6,724	9,650	(15,037)	1,462	17,547	2,494	6,466	4,386	-	20,502		

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Nine months ended September 30, 2025

	< - Canadian Patient Services - >			< - WELL Health USA Patient and Provider Services - >									
	Primary - WMC	Specialized - WDC	Total	Primary - Circle Medical	Primary - WISP	Specialized - CRH Medical	Specialized - Provider Staffing	Total	SAAS and Technology Services	HEALWELL	Total - All segments	Corporate / Elimination	Grand total
Total segment revenue	200,037	125,280	325,317	105,651	87,868	205,385	159,070	557,974	63,359	79,061	1,025,711	11,834	1,037,545
Inter-segment revenue	(745)	(389)	(1,134)	-	-	-	(2,257)	(2,257)	(6,244)	(667)	(10,302)	(11,834)	(22,136)
Revenue from external customers	199,292	124,891	324,183	105,651	87,868	205,385	156,813	555,717	57,115	78,394	1,015,409	-	1,015,409
Cost of sales	(136,950)	(48,683)	(185,633)	(39,486)	(24,318)	(127,897)	(140,703)	(332,404)	(11,901)	(38,102)	(568,040)	(5,387)	(573,427)
Salaries and benefits	(27,012)	(31,474)	(58,486)	(16,361)	(9,164)	(14,907)	(1,409)	(41,841)	(20,973)	(24,461)	(145,761)	(10,387)	(156,148)
Marketing and promotion	(914)	(528)	(1,442)	(12,156)	(47,499)	(706)	(159)	(60,520)	(459)	(6,298)	(68,719)	(786)	(69,505)
Other G&A	(21,551)	(11,416)	(32,967)	(9,610)	(4,260)	(9,857)	(2,376)	(26,103)	(6,795)	(5,964)	(71,829)	(7,271)	(79,100)
Operating expenses	(186,427)	(92,101)	(278,528)	(77,613)	(85,241)	(153,367)	(144,647)	(460,868)	(40,128)	(74,825)	(854,349)	(23,831)	(878,180)
Adjusted EBITDA	12,865	32,790	45,655	28,038	2,627	52,018	12,166	94,849	16,987	3,569	161,060		

Nine months ended September 30, 2024 ("Restated", refer to Note 2 (c))

	< - Canadian Patient Services - >			< - WELL Health USA Patient and Provider Services - >									
	Primary - WMC	Specialized - WDC	Total	Primary - Circle Medical	Primary - WISP	Specialized - CRH Medical	Specialized - Provider Staffing	Total	SAAS and Technology Services	HEALWELL	Total - All segments	Corporate / Elimination	Grand total
Total segment revenue	138,795	91,858	230,653	55,858	72,268	189,248	91,399	408,773	51,072	-	690,498	11,931	702,429
Inter-segment revenue	(239)	-	(239)	-	-	(139)	(1,968)	(2,107)	(3,222)	-	(5,568)	(11,931)	(17,499)
Revenue from external customers	138,556	91,858	230,414	55,858	72,268	189,109	89,431	406,666	47,850	-	684,930	-	684,930
Cost of sales	(94,732)	(34,053)	(128,785)	(43,705)	(19,089)	(116,695)	(80,327)	(259,816)	(16,705)	-	(405,306)	711	(404,595)
Salaries and benefits	(19,932)	(26,732)	(46,664)	(14,694)	(8,202)	(14,444)	(572)	(37,912)	(17,145)	-	(101,721)	(7,821)	(109,542)
Marketing and promotion	(690)	(425)	(1,115)	(20,753)	(38,295)	(805)	(77)	(59,930)	(453)	-	(61,498)	(817)	(62,315)
Other G&A	(14,302)	(9,589)	(23,891)	(12,459)	(3,556)	(6,931)	(1,735)	(24,681)	(1,964)	-	(50,536)	(7,528)	(58,064)
Operating expenses	(129,656)	(70,799)	(200,455)	(91,611)	(69,142)	(138,875)	(82,711)	(382,339)	(36,267)	-	(619,061)	(15,455)	(634,516)
Adjusted EBITDA	8,900	21,059	29,959	(35,753)	3,126	50,234	6,720	24,327	11,583	-	65,869		

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

A reconciliation of income (loss) before income tax to segment Adjusted EBITDA is as follows:

	Three months ended September 30, 2025		September 30, 2024 Restated (Note 2(c))		Nine months ended September 30, 2025		September 30, 2024 Restated (Note 2(c))	
Adjusted EBITDA	68,679		20,502		161,060		65,869	
Corporate expenses	(8,762)		(5,368)		(23,831)		(15,455)	
Depreciation and amortization	(26,520)		(17,476)		(71,461)		(51,343)	
Interest expense	(16,228)		(9,103)		(40,543)		(28,333)	
Interest income	342		255		1,324		772	
Rent expense on finance leases	4,935		4,675		15,030		12,918	
Share-based payments	(5,949)		(2,141)		(14,229)		(12,383)	
Foreign exchange (loss) gain	(1,734)		(62)		(786)		42	
Time-based earnout expense	(1,583)		(1,829)		(6,935)		(3,956)	
Change in fair value of investments	(311)		(77,092)		(22,795)		53,192	
Change in fair value of derivative liability	(488)		-		1,642		-	
Gain on disposal of assets and investments	10,950		33		10,974		11,317	
Share of net loss of associates	(146)		(1,832)		(2,643)		(2,719)	
Transaction, restructuring and integration expenses	(3,946)		(2,002)		(10,612)		(8,189)	
Legal settlement and defense recovery (costs)	(1,824)		(829)		1,780		(2,723)	
Impairment charge and other items	(10,506)		-		(11,260)		(753)	
Income (loss) before income tax	6,909		(92,269)		(13,285)		18,256	

Geographic information

Revenue by geographic location of customers for the three and nine months ended September 30, 2025, and 2024 are summarized as follows:

Three months ended September 30, 2025 and 2024

	US		Canada		Others		Canada (Corporate / Shared services)		Total	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Total segment revenue	203,550	141,246	152,855	94,639	12,016	-	4,910	3,919	373,331	239,804
Inter-segment revenue	(1,415)	(654)	(2,407)	(1,096)	-	-	(4,910)	(3,919)	(8,732)	(5,669)
Revenue from external customers	202,135	140,592	150,448	93,543	12,016	-	-	-	364,599	234,135

Nine months ended September 30, 2025 and 2024

	US		Canada		Others		Canada (Corporate / Shared services)		Total	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
Total segment revenue	567,685	408,773	432,772	281,725	25,254	-	11,834	11,931	1,037,545	702,429
Inter-segment revenue	(2,257)	(2,107)	(8,045)	(3,461)	-	-	(11,834)	(11,931)	(22,136)	(17,499)
Revenue from external customers	565,428	406,666	424,727	278,264	25,254	-	-	-	1,015,409	684,930

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Non-current assets other than financial instruments and deferred tax assets by location are summarized as at September 30, 2025 and December 31, 2024:

	September 30, 2025	December 31, 2024
US	647,647	635,571
Canada	840,414	603,857
Others	129,226	-
Canada (Corporate / Shared Services)	4,430	21,668
Total	1,621,717	1,261,096

19. Business Combinations, Asset Acquisitions and Disposals

The Company completed multiple business combinations and asset acquisitions during the nine months ended September 30, 2025.

The purchase price of these acquisitions was satisfied through, where applicable:

- (i) cash paid to the vendor, net of working capital adjustments;
- (ii) fair value of common shares of the Company issued to the vendor, determined at the opening share price on the date of the issuance;
- (iii) fair value of common shares of a Company subsidiary issued to the vendor, determined as of the date of the issuance;
- (iv) working capital/indemnification holdback; and
- (v) deferred purchase consideration in the form of contingent consideration that is treated as a deferred acquisition cost.

For business combinations, the excess of the fair value of the purchase consideration over the fair values of assets and liabilities acquired is recognized as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired businesses. The Company elected to recognize the non-controlling interests at its proportionate share of the acquired net identifiable assets, where applicable.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(a) 2025 acquisitions and disposals:

- (i) During the nine months ended September 30, 2025, the Company acquired interests in the following companies:

Company name	Date of Acquisition	Business/asset acquisition	% Ownership	Place of incorporation	Line of business
Harmony Anesthesia, LLC ("Harmony")	January 1, 2025	Business	65%	US	WELL Health USA Patient and Provider Services – Specialized CRH
Bison Family Medical Clinic Inc. ("Bison")	February 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
2622292 Ontario Inc. dba Healthpoint Medicine, Northpoint Family Medicine Inc. ("Healthpoint/Northpoint")	March 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
K-2 Cardiac Care Inc. ("K-2")	April 1, 2025	Business	100%	Canada	Canadian Patient Services – Specialized WDC
Meadowlands Family Practice ("Meadowlands")	April 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
HEALWELL AI Inc. ("HEALWELL")	April 1, 2025	Business	37%	Canada	HEALWELL
Myrtle Beach Anesthesia Associates, LLC ("MBAA")	May 1, 2025	Asset	51%	US	WELL Health USA Patient and Provider Services – Specialized CRH
Northern Georgia Anesthesia Associates, LLC ("NGAA")	May 19, 2025	Asset	51%	US	WELL Health USA Patient and Provider Services – Specialized CRH
1692040 Ontario Inc. dba Patient Networks ("Patient Networks")	June 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
Kensington Medical Clinic Inc. ("Kensington")	July 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
Preventum Health Management Ltd. ("Preventum")	July 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
MyCardia Clinic ("MyCardia")	August 1, 2025	Asset	100%	Canada	Canadian Patient Services – Primary
ReGen Scientific Inc. ("ReGen")	August 1, 2025	Business	100%	Canada	Canadian Patient Services – Primary
Halton Family Health Centre Inc. ("Halton")	September 1, 2025	Asset	100%	Canada	Canadian Patient Services – Primary
Greater Ocala Anesthesia Associates, LLC ("GOAA")	September 1, 2025	Asset	51%	US	WELL Health USA Patient and Provider Services – Specialized CRH

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

The following table summarizes the fair value of the purchase consideration and the estimated fair values of assets and liabilities acquired at the acquisition dates for business combinations and asset acquisitions that occurred during the nine months ended September 30, 2025. Purchase price allocations have been classified as "Final" or "Provisional"/"Prov" based on the status of the work performed by the Company to determine net working capital or other adjustments and the fair value of the assets acquired and liabilities assumed at the acquisition date. The Company may adjust preliminary purchase price allocations, as necessary, up to one year after the acquisition closing date as new information is obtained about facts and circumstances that existed as of the closing date.

	Harmony	Bison	Healthpoint/ Northpoint	NGAA	Patient Networks	Kensington	Preventum	Halton	ReGen	Others *	Total
	Final	Prov	Prov	Final	Prov	Prov	Prov	Prov	Prov		
Cash	31,702	1,871	5,797	5,713	2,071	5,369	11,068	4,629	3,650	2,912	74,782
Indemnity holdback	-	159	649	-	300	-	-	-	-	94	1,202
Working capital holdback	-	80	226	-	-	506	1,770	315	300	53	3,250
Deferred acquisition cost (Note 11(a))	1,423	1,101	1,816	-	1,630	865	-	1,833	1,460	867	10,995
Acquisition-related transaction cost	-	-	-	97	-	-	-	-	-	126	223
Purchase consideration	33,125	3,211	8,488	5,810	4,001	6,740	12,838	6,777	5,410	4,052	90,452
Assets and liabilities acquired											
Cash	1,013	47	1	-	29	101	592	-	49	207	2,040
Accounts receivable and other current assets	8,803	88	302	-	266	194	674	-	107	112	10,547
Other current assets	-	96	198	-	2	6	12	-	60	-	373
Property and Equipment	-	187	181	-	-	-	-	-	2,761	21	3,150
Right of use asset	-	1,099	689	-	159	493	264	2,449	3,931	412	9,496
Accounts payable	(605)	(117)	(18)	-	(142)	(255)	(131)	-	(325)	(89)	(1,682)
Other current liabilities	-	-	-	-	(33)	-	-	-	-	-	(33)
Lease liabilities	-	(1,099)	(689)	-	(159)	(493)	(264)	(2,449)	(3,931)	(412)	(9,496)
Deferred Revenue	(549)	-	-	-	-	-	(2,467)	-	(622)	-	(3,638)
Non-controlling interest	(17,836)	-	-	(5,583)	-	-	-	-	-	(1,586)	(25,005)
Exclusive professional services agreement ("PSA")	16,004	-	-	11,393	-	-	-	-	-	3,235	30,632
Brand (Note 10)	8,795	-	-	-	-	-	-	-	-	-	8,795
Goodwill (Note 10)	17,499	2,909	7,823	-	3,878	6,694	14,158	6,777	3,380	2,152	65,271
	33,125	3,211	8,488	5,810	4,001	6,740	12,838	6,777	5,410	4,052	90,452
PSA Amortization Period	15 years			15 years						15 years	

* K-2, MBAA, GOAA, Meadowlands, MyCardia

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

As at September 30, 2025, goodwill of \$47,772 acquired in business combinations within the Canadian Patient Services – Primary segment is primarily attributable to acquired workforces, expansion of market share, and expected synergies to be realized within the Company's clinic network. The goodwill acquired is not deductible for tax purposes.

As at September 30, 2025, goodwill of \$17,499 acquired in business combinations within the WELL Health USA Patient and Provider Services – Specialized Provider Staffing segment primarily attributable to acquired workforces, expansion of market share, and expected synergies to be realized within the Company's provider services network. Of the total goodwill acquired, \$16,198 is deductible for tax purposes.

Revenue and net income for acquired businesses included in the Company's condensed interim consolidated financial statements for the nine months ended September 30, 2025, from the date of acquisition of each business are as follows:

	Harmony	Bison	Healthpoint/ Northpoint	NGAA	Patient Networks	Kensington	Preventum	Halton	Other
Revenue	54,874	7,052	9,084	2,522	1,282	2,109	1,301	1,131	3,129
Net income	6,172	34	158	708	139	343	620	143	424

The Company has not disclosed pro forma revenue and net income for the nine months ended September 30, 2025, as if the acquisitions had occurred on January 1, 2025, because it is impracticable to do so. The financial records of certain acquired companies were not maintained in a manner that allows for the preparation of IFRS-compliant financial information for the full year without undue effort or cost.

(ii) Acquisition of control and consolidation of HEALWELL

On April 1, 2025, the Company completed the step acquisition of HEALWELL (Note 11(a)). HEALWELL is a healthcare artificial intelligence company focused on preventative care with a mission to improve healthcare and save lives through early identification and detection of disease. The Company began consolidating 100% of the assets, liabilities and results of operations of HEALWELL as a subsidiary of the Company from the date of acquisition of April 1, 2025. The Company acquired a controlling interest in HEALWELL on April 1, 2025. The Company has been advised that the acquisition of such controlling interest in HEALWELL is subject to review by the Canadian Competition Bureau (the "CCB"). The timing and outcome around such review is uncertain. Under the Competition Act, the CCB has broad investigatory and enforcement powers, including the ability to require the Company to dispose of select assets. Additionally, an extended review by the CCB will result in compliance costs and diversion of management's attention. The acquisition date, as defined under IFRS 3, was determined as April 1, 2025 and the date that control was transferred.

As part of the step acquisition of control, the Company remeasured its previously held equity interest in HEALWELL, the call option for the Class A Subordinate Voting Shares and the call option for the Class B Multiple Voting Shares to fair value immediately prior to the acquisition of control on April 1, 2025. Total purchase consideration of \$142,918 consisted of the fair value of WELL's equity method investment in HEALWELL of \$97,642, fair value of the call option of the Class A Subordinate Voting Shares and Class B Multiple Voting Shares of \$41,423 and cash paid for the exercise of the call options of \$3,853.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Goodwill of \$128,210 is attributable to the workforce, expected synergies and future profitability of the acquired businesses. The goodwill is not deductible for tax purposes. The Company elected to recognize the non-controlling interest at its proportionate share of the acquired net identifiable assets.

The following table summarizes the fair value of consideration paid on the acquisition date and assets and liabilities recognized as a result of the acquisition. In determining the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of HEALWELL's business. The Company has not yet finalized the purchase price allocation. The allocation of the purchase price will be finalized within twelve months following the acquisition date.

Purchase consideration	142,918
Assets and liabilities acquired	
Cash	32,829
Accounts receivables and other current assets	27,509
Contract assets	16,765
Other current assets	8,591
Lease receivable	907
Property and equipment	1,346
Right of use asset	7,744
Accounts payable	(30,245)
Other current liabilities	(22,840)
Contract liabilities	(23,100)
Deferred acquisition costs	(25,576)
Lease liabilities	(11,062)
Notes payable and other borrowings – current	(1,000)
Notes payable and other borrowings – non-current	(45,356)
Convertible debentures – current	(23,272)
Convertible debentures – non-current	(5,270)
Deferred tax liability	(19,056)
Non-controlling interest	(73,108)
Customer relationships (Note 12)	116,216
Brand (Note 12)	24,327
Technology (Note 12)	58,359
Goodwill (Note 12)	128,210
	142,918

Revenue of \$78,394 and net loss of \$32,349 for HEALWELL is included in the Company's condensed interim consolidated financial statements for the nine months ended September 30, 2025, from the date of acquisition.

If the acquisitions had occurred on January 1, 2025, the pro forma revenue for the nine months ended September 30, 2025 would have been \$92,482 and net loss of \$46,404.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

On July 14, 2025, HEALWELL exercised its call option and acquired the remaining 49% of the issued and outstanding shares of Pentavere from the non-controlling shareholders for total consideration of \$14,937. The purchase price was settled through the issuance of 10,161,562 HEALWELL Subordinate Voting Shares at the closing share price of \$1.47 per share on July 14, 2025. As a result of this transaction, Pentavere became a wholly-owned subsidiary of HEALWELL and the call option was derecognized (fair value of \$nil at September 30, 2025; December 31, 2024 – \$nil). The transaction was accounted for as an equity transaction, as it represented a change in ownership interest without a loss of control. Accordingly, the non-controlling interest and call option were derecognized, and the difference between the fair value of the shares issued and the carrying value of the non-controlling interest was recognized directly to deficit.

The share purchase agreement between Mutuo and HEALWELL included a call option to purchase the remaining ownership interest in Mutuo. HEALWELL modeled the probability of exercising the call option and used the Black Scholes method to model the option itself to arrive at a fair value of \$796 as at September 30, 2025 (December 31, 2024 - \$nil). During the period ended September 30, 2025, the change in fair value of \$704 (December 31, 2024 - \$nil) has been recognized in the consolidated statement of income (loss) and comprehensive income (loss).

(iii) 2025 disposals

On September 30, 2025, the Company sold its 51% interest in Lake Washington Anesthesia Associates, LLC ("LWA").

The Company received \$15,337 (US\$11,087) in total consideration (US\$10,464 in cash and US\$623 escrow receivable) for its 51% interest in the LWA business. Disposal costs of US\$170 were incurred in relation to this transaction and are included in the net gain on disposal. The sale price is provisional at closing to be evaluated 90 days after the effective date. The overall gain on disposal of this transaction was \$11,174 (US\$8,078).

(b) 2024 acquisitions and disposals

(i) 2024 acquisitions

During the nine months ended September 30, 2025, the Company finalized the purchase accounting for the 2024 acquisitions of BlueBird IT Solutions Inc. ("BBS"), Microquest Inc. ("MQS"), Jack Nathan Medical Clinics ("JNM") and other 2024 acquisitions with adjustments as shown in the table below:

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

	NDA Final	BBS			MQS			JNM Final	Other*			Total
		Prov.	Adj.	Final	Prov.	Adj.	Final		Prov.	Adj.	Final	
Cash	10,170	3,293	-	3,293	13,250	-	13,250	5,000	7,097	-	7,097	38,810
Fair value of subsidiary's shares issued at closing	-	3,896	-	3,896	-	-	-	-	-	-	-	3,896
Working capital holdback	-	964	(162)	802	846	20	866	-	524	(380)	144	1,812
Deferred acquisition cost (Note 14(a))	-	244	-	244	1,971	-	1,971	-	2,315	-	2,315	4,530
Acquisition-related transaction cost	124	-	-	-	-	-	-	-	-	-	-	124
Purchase consideration	10,294	8,397	(162)	8,235	16,067	20	16,087	5,000	9,936	(380)	9,556	49,172
Assets and liabilities acquired												
Cash	-	66	-	66	297	-	297	-	1,374	-	1,374	1,737
Accounts receivable and other current assets	-	1,223	(65)	1,158	715	(1)	714	-	1,301	26	1,327	3,199
Other current assets	-	85	(5)	80	63	(9)	54	-	58	(37)	21	155
Property and equipment	-	-	-	-	-	-	-	571	208	-	208	779
Right of use asset	-	-	-	-	-	-	-	-	2,623	-	2,623	2,623
Accounts payable	-	(563)	(14)	(577)	(147)	-	(147)	-	(1,719)	(16)	(1,735)	(2,459)
Other current liabilities	-	-	(78)	(78)	(102)	30	(72)	(54)	(234)	(253)	(487)	(691)
Lease liabilities	-	-	-	-	-	-	-	-	(2,623)	-	(2,623)	(2,623)
Deferred tax liability	-	(921)	-	(921)	(2,341)	-	(2,341)	-	-	-	-	(3,262)
Non-controlling interest	(9,891)	(397)	-	(397)	-	-	-	-	(431)	138	(293)	(10,581)
Exclusive professional services agreement ("PSA") (Note 12)	20,185	-	-	-	-	-	-	-	-	-	-	20,185
Technology (Note 12)	-	-	-	-	2,993	-	2,993	-	-	-	-	2,993
Customer relationship (Note 12)	-	3,409	-	3,409	5,614	-	5,614	-	-	-	-	9,023
Goodwill (Note 12)	-	5,495	-	5,495	8,975	-	8,975	4,483	9,379	(238)	9,141	28,094
	10,294	8,397	(162)	8,235	16,067	20	16,087	5,000	9,936	(380)	9,556	49,172

PSA amortization term

15 years

* PFY, Pacific Medical, The Health Clinic by Shoppers, C-Health, 19th & Lonsdale Medical Corporations, Wilson Centre Family Practice, S.J. Stemplowski Psychotherapy Professional Corporation, HMC, and Medical Associates of Meadowvale.

(ii) 2024 disposals

On February 1, 2024, the Company completed the sale of Intrahealth, an EMR provider within the Company's SaaS and Technology Services reportable segment, to HEALWELL for total consideration of \$24,361 consisting of cash of \$3,152, shares in HEALWELL with fair value of \$14,961, a holdback receivable of \$606 and other deferred payments of \$5,642. The gain on disposal before tax was \$11,750.

20. Contingencies

In the ordinary course of business, the Company is involved in and potentially subject to, legal actions and proceedings. There are many uncertainties involved in these legal actions and proceedings and as such, it is not possible for the Company to predict the final outcome of these matters with certainty. The Company does not believe that the ultimate resolution of these matters, including the matters noted below where not fully resolved, will have a material adverse impact on the Company's operations, financial condition or results of operations.

Since November 2023, the Company's subsidiary WISP, Inc. ("WISP") has had two class actions and one mass arbitration filed against it, each alleging pixel tracking technologies deployed on WISP's website used to improve marketing and advertising initiatives, improperly collected and disclosed personal health information to third-party social media platforms (Meta Platforms Inc. dba Facebook, Google, Bing/Microsoft, and Tik Tok Inc.). WISP has settled the class actions and the mass arbitration matters, with one class action settlement pending final court approval. For the year ended December 31, 2024, the Company recognized an expense of \$6,017 in other expenses for estimated settlement costs and \$290 in general and administrative expenses for legal fees. During the nine months ended September 30, 2025, the Company reached an agreement to settle an insurance claim in relation to this matter and recognized an insurance recovery of \$2,085 as other income in the consolidated statement of loss for

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

the nine months ended September 30, 2025, and as other receivables on the consolidated statement of financial position as of September 30, 2025.

In September 2024, the Company's 70%-owned Delaware subsidiary, Circle Medical Technologies, Inc. ("Circle Medical"), received a Request for Information ("RFI") from the Civil Division of the United States Attorney's Office for the Northern District of California ("USAO") relating to claims for reimbursement submitted to both federal health care programs and private insurers. Circle Medical voluntarily responded to the RFI and discussions with the USAO regarding this matter are ongoing. The Company cannot predict the outcome of the RFI, nor the length of time it may take to resolve the RFI, or other related actions that might ensue. For the year ended December 31, 2024, the Company recognized an expense of \$4,072 in other expenses for estimated settlement costs and \$511 in general and administrative expenses for legal fees. For the nine months ended September 30, 2025, the Company incurred \$682 in general and administrative expenses for legal fees and did not recognize any additional settlement expense in relation to this matter.

In 2024, the Company's subsidiary CRH received notice of a product liability claim related to its O'Regan hemorrhoid banding device. Settlement of the claim occurred in April 2025. For the year ended December 31, 2024, the Company recognized an expense of \$7,914 in other expenses for settlement costs and \$100 in general and administrative expenses for legal fees. In April 2025, the Company reached an agreement to settle an insurance claim in relation to this matter in the amount of \$4,474.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

21. Financial Instruments

(a) Classification of financial instruments

The following table summarizes the Company's financial instruments and their carrying amounts:

	September 30, 2025	December 31, 2024
Financial assets at amortized cost		
Cash and cash equivalents	82,546	131,669
Accounts and other receivables	198,509	184,505
Other current and non-current assets	48,114	32,193
	329,169	348,367
Financial assets at fair value through profit or loss ("FVPL")		
Equity and debt investments	14,717	158,476
Financial liabilities at amortized cost		
Accounts payable and accrued liabilities	107,270	86,583
Loans and borrowings	395,610	290,265
Convertible debentures	89,317	55,094
Redeemable preferred shares	53,744	48,054
Lease liability	90,868	79,730
Advances payable	69,527	165,441
Other current and non-current liabilities	44,974	30,274
	851,310	755,441
Financial liabilities at fair value through profit or loss ("FVPL")		
Deferred acquisition costs	60,711	30,939

(b) Fair value measurements

The fair value hierarchy establishes three levels to reflect the significance of the inputs used in making the measurements:

Level 1 – quoted prices in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial instruments are classified based on the lowest level of input that is significant to the fair value measurement of the asset or liability. There were no transfers of fair value measurements between level 1, 2 and level 3 of the fair value hierarchy for the nine months ended September 30, 2025 and for year ended December 31, 2024.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Financial instruments carried at amortized cost:

The carrying values of cash and cash equivalents, accounts and other receivables, contract assets, accounts payable and accrued liabilities, lease liability, advances payable and certain other assets and liabilities measured at amortized cost, approximate their carrying value due to the short-term maturities of these instruments.

The Company's loans and borrowings, which are mainly comprised of the JPM facility, the RBC facility, and the BNS facility (Note 15(a)), are floating rate instruments which are based on SOFR plus 1.75% to 3.00% dependent on CRH's total leverage ratio, CORRA plus 1.50% to 3.25% dependent on WHCC and MyHealth's total funded debt to EBITDA ratio, and CORRA plus 1.65% to 3.15% dependent on Orion Health's net debt to EBITDA ratio, respectively. The Company estimated the fair value of these financial instruments to be \$220,301 for the JPM facility, \$126,200 for the RBC facility, and \$49,000 for the BNS facility as at September 30, 2025 based on a discounted cash flow analysis using Level 2 directly observable market inputs (December 31, 2024 - \$195,918 for the JPM facility, and \$92,575 for the RBC facility).

The fair value of the Company's convertible debentures issued in 2021, including the equity component, was \$70,350 as of September 30, 2025 (December 31, 2024 - \$71,750), based on the Level 1 quoted market price of the convertible debentures on that date.

The fair value of the Company's redeemable preferred shares issued by its subsidiary, WELLSTAR (Note 15(c)), was estimated to be \$55,350 as of September 30, 2025 (December 31, 2024 - \$50,378).

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

(c) Financial risk management

Liquidity risk

The maturities of the contractual cash flows of the Company's financial liabilities are as follows:

At September 30, 2025	Total	<i>Undiscounted payments due by period</i>			
		Less than 1 year	1-3 years	4-5 years	More than 5 years
Deferred acquisition costs and time-based earnouts	98,487	29,418	42,239	10,410	16,420
Lease obligations' minimum payments	104,340	26,489	39,810	22,666	15,375
Accounts payable and accrued liabilities	107,270	107,270	-	-	-
Working capital holdbacks	4,296	4,296	-	-	-
Advances payable	69,527	69,527	-	-	-
Other current and non-current liabilities	36,711	34,474	2,237	-	-
Loans and borrowings	396,099	7,328	388,771	-	-
Convertible debentures	119,275	6,850	77,925	34,500	-
	936,005	285,652	550,982	67,576	31,795

On March 28, 2024, the Company entered into an agreement with a cloud hosting services provider to secure infrastructure services for its operations. Pursuant to this agreement, the Company and its affiliates have committed to spending a total of \$25,000 over a period of five years. As of September 30, 2025, the Company had a remaining commitment of \$19,008 under this agreement.

On July 31, 2025, the Company entered into an agreement with a cloud hosting services provider to secure infrastructure services for its operations. Pursuant to this agreement, the Company and its affiliates have committed to spending a total of \$50,434 over a period of five years. As of September 30, 2025, the Company had a remaining commitment of \$49,264 under this agreement.

Interest rate risk

The Company is exposed to fluctuations in interest rates through variable rate debt obligations under its syndicated credit facilities with JPM, RBC and BNS (Note 15(a)). The Company from time-to-time uses interest rate swap contracts to hedge the variability of the cash flows attributable to changes in the relevant benchmark variable interest rates.

With all other variables held constant, a 10% upward movement in the interest rate would have increased net loss by approximately \$1,762 and \$1,532 for the nine months ended September 30, 2025 and 2024, respectively. There would be an equal and opposite impact on net loss with a 10% downward movement in the interest rate.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

Foreign currency risk

The Company is exposed to foreign exchange risk on revenue contracts, purchase contracts and loans and borrowings denominated in currencies other than the currency of the Company's contracting entity. For Canadian operations, this is typically the U.S. dollar and for U.S. entities, this is typically the Canadian dollar. The Company is also exposed to foreign currency risk on translation of the net assets of its foreign operations to Canadian dollars.

The Company from time-to-time uses foreign currency forward contracts to manage its exposure to transactions in foreign currencies. These transactions include forecasted transactions and firm commitments denominated in foreign currencies.

The Company had no foreign currency forward contracts outstanding as at September 30, 2025 and December 31, 2024.

The Company operates internationally and is exposed to currency risk on transactions that are denominated in a currency other than the functional currency of the relevant group entity and is primarily exposed to risk in the following currencies: US Dollar (USD), New Zealand Dollar (NZD), Australian Dollar (AUD), Pound Sterling (GBP), EURO (EUR), and United Arab Emirates Dirham (AED).

The Company's exposure to foreign currency risk at the reporting date was as follows (all amounts are denominated in CAD):

	NZD CAD	AUD CAD	GBP CAD	USD CAD	EUR CAD	AED CAD
As at September 30, 2025						
Cash and cash equivalents	1,230	1,688	1,845	28,937	583	35
Trade receivables	3,297	306	2,773	127,857	510	-
Trade payables	(1,241)	(208)	(375)	(51,508)	(295)	(13)
Advances payable	-	-	-	(69,527)	-	-
Loans and borrowings	-	-	-	(219,364)	-	-
Net exposure	3,286	1,786	4,243	(183,605)	798	22

The following table summarizes the sensitivity of profit and loss and equity with regards to the Company's financial assets and financial liabilities affected by foreign currency/CAD exchange rate with all other aspects being equal. A positive number below indicates an increase in profit and equity where CAD strengthens 10% against the relevant currency for the period ended September 30, 2025. For a 10% weakening of CAD against the relevant currency for the period ended September 30, 2025, there would be a comparable impact of the profit and equity in the opposite direction.

	NZD CAD	AUD CAD	GBP CAD	USD CAD	EUR CAD	AED CAD
As at September 30, 2025						
Profit or loss	-	-	-	-	-	-
Equity	(299)	(162)	(386)	16,691	(73)	(2)

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

22. Cash Flow Information

	Nine months ended	
	September 30,	September 30,
	2025	2024
		Restated
Change in non-cash operating items:		
Accounts and other receivables	19,265	(115,623)
Contract assets	(3,671)	-
Inventory	453	(737)
Prepayments and other current assets	(10,881)	(7,755)
Other non-current assets	3,248	1,633
Accounts payable and accrued liabilities	(11,749)	17,754
Deferred revenue	(18,919)	41,988
Contract liabilities	(1,317)	-
Other non-current liabilities	(12,768)	(1,434)
Other current liabilities	2,600	4,380
	(33,739)	(59,794)
	Nine months ended	
	September 30,	September 30,
	2025	2024
Equity and debt investments in associates and others:		
Equity investment in Longevity AI	(1,432)	-
Equity investment in HEALWELL	(5,375)	-
Investment in doctorly	-	(73)
	(6,807)	(73)

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

	Nine months ended	
	September 30, 2025	September 30, 2024
Business acquisitions, net of cash acquired (Note 19):		
Harmony	(30,689)	-
Bison	(1,824)	-
Healthpoint/Northpoint	(5,796)	-
Meadowlands	(695)	-
Patient Networks	(2,042)	-
K2	(304)	-
HEALWELL	28,976	-
Kensington	(5,268)	-
Preventum	(10,476)	-
Regen	(3,601)	-
Shoppers	-	(100)
Pacific Medical	-	(1,047)
	(31,719)	(1,147)
Asset acquisitions (Note 19):		
MBAA	(928)	-
NGAA	(5,509)	-
MyCardia	(404)	-
Halton	(4,628)	-
GOAA	(312)	-
	(11,781)	-

For the nine months ended September 30, 2025, \$154,511 of the purchase consideration of business and assets acquisitions included the following non-cash consideration, fair values of shares previously acquired (\$139,064), and deferred acquisition costs and working capital holdback (\$15,447) to be paid over time. For the nine months ended September 30, 2024, the Company completed the sale of a subsidiary for a total consideration of \$24,361 to HEALWELL, \$14,961 was received via HEALWELL shares, \$606 via a holdback receivable, and \$5,642 in other deferred payments.

For the nine months ended September 30, 2025, \$11,285 of the deferred acquisition costs were financed by the issuance of WELL's shares (2024 - \$6,899); and the additions of right-of-use assets in the amount of \$8,014 (2024 - \$7,158) were financed by lease liabilities.

WELL HEALTH TECHNOLOGIES CORP.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited, expressed in thousands of Canadian dollars unless otherwise stated, except share and per share amounts)

23. Events After the Reporting Period

On October 31, 2025, the Company announced its majority-owned subsidiary, WELLSTAR, has entered into agreements to complete a Series B Preferred Share investment in the aggregate amount of approximately \$62,000 at an offering price of C\$1.50 per Series B Share. On the closing of the financing, WELLSTAR will issue \$59,000 of Series B Shares to institutional investors, plus an additional amount of approximately \$3,000 of Series B Shares to management of both WELLSTAR and the Company.